Phase 1 trial data demonstrates safety of hepatic LDHA inhibition across all primary hyperoxaluria types, indicating a universal therapeutic target.
Phase I clinical data on nedosiran and published nonclinical data together provide substantial evidence that LDHA inhibition is a safe therapeutic mechanism for the treatment of all known types of PH.
No takes yet. Share an insight, caveat, or question.
Ariceta et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: